Curanex Pharmaceuticals Inc - Common Stock (CURX)
0.4599
+0.1444 (45.77%)
NASDAQ · Last Trade: Feb 26th, 6:32 PM EST
Detailed Quote
| Previous Close | 0.3155 |
|---|---|
| Open | 0.4820 |
| Bid | 0.4835 |
| Ask | 0.4850 |
| Day's Range | 0.4500 - 0.6666 |
| 52 Week Range | 0.2620 - 0.8466 |
| Volume | 207,324,803 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 1,811,537 |
Chart
News & Press Releases
Avalon GloboCare Corp. (NASDAQ: ALBT), ENDRA Life Sciences Inc. (NASDAQ: NDRA) , Curanex Pharmaceuticals Inc. (NASDAQ: CURX) , and Healthcare Triangle, Inc. (NASDAQ: HCTI) are capturing market attention with strategic technology integrations, clinical validation progress, regulatory manufacturing milestones, and global digital health expansion, driving heightened search activity for AI healthcare equities, biotech pipelines, and short squeeze catalysts.
Via AB Newswire · February 26, 2026
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.chartmill.com
Via Chartmill · February 26, 2026
Thursday's session: most active stockschartmill.com
Via Chartmill · February 26, 2026
Unusual volume stocks are being observed in Thursday's session.chartmill.com
Via Chartmill · February 26, 2026
Thursday's session: top gainers and loserschartmill.com
Via Chartmill · February 26, 2026
There are notable gap-ups and gap-downs in today's session.chartmill.com
Via Chartmill · February 26, 2026
Get insights into the top gainers and losers of Thursday's pre-market session.chartmill.com
Via Chartmill · February 26, 2026
Top movers in Wednesday's after hours sessionchartmill.com
Via Chartmill · February 25, 2026
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.
Via Chartmill · December 3, 2025
The biopharmaceutical landscape is continuously evolving, with the convergence of innovation and tradition unlocking novel therapeutic opportunities. Curanex Pharmaceuticals (NASDAQ: CURX) stands at this promising intersection. As a US-based, preclinical-stage biopharmaceutical company specializing in botanical drug development, Curanex is pioneering new possibilities for addressing a range of complex diseases.
Via Get News · October 23, 2025